<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03242928</url>
  </required_header>
  <id_info>
    <org_study_id>CAFQ056X2201</org_study_id>
    <secondary_id>2017-000736-33</secondary_id>
    <nct_id>NCT03242928</nct_id>
  </id_info>
  <brief_title>Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)</brief_title>
  <official_title>A Randomized, Subject and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will assess whether AFQ056 can have a beneficial effect by reducing cocaine use in
      Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Anticipated">March 11, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to evaluate the effect of AFQ056 in reducing cocaine use.</measure>
    <time_frame>Daily from screening (Day-28 to -9) to Day 113</time_frame>
    <description>The Timeline Follow-Back (TLFB) cocaine self-report is an assessment method that obtains estimates of daily cocaine intake and has been evaluated with clinical and nonclinical populations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of on other measures of cocaine use</measure>
    <time_frame>Days: 28 to -9; -10 to -8; -7 to -4; -3 to -1; 1; 4; 8; 11; 15; 18; 22; 25; 29; 32; 36; 39; 43; 46; 50; 53; 57; 60; 64; 67; 71; 74; 78; 81; 85; 88; 92; 95; 98; 99; 102; 106; 112; 113</time_frame>
    <description>Urine sample will be analyzed for the presence of cocaine metabolite's Benzoylecgonine (BE) the main metabolite of cocaine present in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects on alcohol use</measure>
    <time_frame>Daily from screening (Day-28 to -9) to Day 113</time_frame>
    <description>The Timeline Follow-Back (TLFB) alcohol is a drinking assessment method that obtains estimates of daily drinking and has been evaluated with clinical and nonclinical populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFQ056 plasma concentrations</measure>
    <time_frame>Day 15 (0h, 2h), Day 29 (0, 2h), Day 57 (0h, 2h), Day 98 (0h,2h)</time_frame>
    <description>Plasma samples will be collected to assess PK.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cocaine-related Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AFQ056</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFQ056</intervention_name>
    <description>Tablets</description>
    <arm_group_label>AFQ056</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand the study procedures and provide written informed consent before any
             assessment is performed.

          -  Subjects diagnosed with Cocaine Use Disorder according to DSM 5 (Diagnostic and
             Statistical Manual of Mental Disorders, 5th Ed.).

          -  Must use cocaine through snorting (intranasally) as primary route of administration.

          -  Recent cocaine use confirmed by positive urine screen for 1 or more benzoylecgonine
             (BE).

          -  Must be seeking treatment for cocaine dependence and have a desire to reduce or cease
             cocaine use.

        Exclusion Criteria:

          -  Has current diagnosis of Substance Use Disorder (according to the DSM 5) on alcohol,
             cannabis or other stimulants, except cocaine.

          -  Meets current or lifetime DSM 5 criteria for schizophrenia or any psychotic disorder,
             or organic mental disorder.

          -  Have current treatment for Substance Use Disorder (e.g.: disulfiram, acamprosate,
             methyl phenidate, modafinil, topiramate, immediate release dexamfetamine,or baclofen).

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test

          -  Have a history of any illness, condition, and use of medications that in the opinion
             of the investigator or designee might confound the results of the study or pose
             additional risk in administering the investigational agents to the subject or preclude
             successful completion of the study

          -  Current or/and previous treatment with concomitant medications that are strong or
             moderate inducers/inhibitors of CYP3A4 (e.g., clarithromycin, ketoconazole, ritonavir,
             etc.)

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV).

          -  Score &quot;yes&quot; on item 4 or item 5 of the Suicidal Ideation section of the CSSRS, if this
             ideation occurred in the past 6 months, or &quot;yes&quot; on any item of the Suicidal Behavior
             section, except for the &quot;Non-Suicidal Self-Injurious Behavior&quot; (item also included in
             the Suicidal Behavior section), if this behavior occurred in the past 2 years.

          -  Controlled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>clinicaltrial.enquiries@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Juan de Alicante</city>
        <state>Alicante</state>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4025</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine Use Disorder; cocaine dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to to respect the privacy of patients who have participated in the trail in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalsutdydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

